The Role of NRF2 in Trinucleotide Repeat Expansion Disorders

• Published in: Antioxidants Vol. 13; no. 6; p. 649
• Main Authors: Chang, Kuo-Hsuan, Chen, Chiung-Mei
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 26.05.2024; MDPI
• Subjects: Amino acids; Animal models; animals; anti-oxidative therapy; antioxidant activity; Antioxidants; Atrophy; Cell culture; Curcumin; dimethyl fumarate; Disease; DNA methylation; Enzymes; Gene expression; Genes; Kinases; microsatellite repeats; neurodegeneration; Neurodegenerative diseases; Neuroprotection; NRF2; NRF2 protein; Oxidative stress; pathogenesis; Protein interaction; Proteins; Reactive oxygen species; Resveratrol; Review; RNA; Sulforaphane; therapeutics; trinucleotide repeat expansion disorders; neurodegeneration; trinucleotide repeat expansion disorders; NRF2; anti-oxidative therapy; oxidative stress
• ISSN: 2076-3921; 2076-3921
• DOI: 10.3390/antiox13060649

Trinucleotide repeat expansion disorders, a diverse group of neurodegenerative diseases, are caused by abnormal expansions within specific genes. These expansions trigger a cascade of cellular damage, including protein aggregation and abnormal RNA binding. A key contributor to this damage is oxidative stress, an imbalance of reactive oxygen species that harms cellular components. This review explores the interplay between oxidative stress and the NRF2 pathway in these disorders. NRF2 acts as the master regulator of the cellular antioxidant response, orchestrating the expression of enzymes that combat oxidative stress. Trinucleotide repeat expansion disorders often exhibit impaired NRF2 signaling, resulting in inadequate responses to excessive ROS production. NRF2 activation has been shown to upregulate antioxidative gene expression, effectively alleviating oxidative stress damage. NRF2 activators, such as omaveloxolone, vatiquinone, curcumin, sulforaphane, dimethyl fumarate, and resveratrol, demonstrate neuroprotective effects by reducing oxidative stress in experimental cell and animal models of these diseases. However, translating these findings into successful clinical applications requires further research. In this article, we review the literature supporting the role of NRF2 in the pathogenesis of these diseases and the potential therapeutics of NRF2 activators.